FY2016 EPS Estimates for Shire PLC Lifted by Analyst (SHPG)
Shire PLC (NASDAQ:SHPG) – Analysts at SunTrust Banks boosted their FY2016 earnings per share (EPS) estimates for shares of Shire PLC in a research note issued to investors on Tuesday. SunTrust Banks analyst J. Boris now expects that the firm will post earnings per share of $13.05 for the year, up from their prior forecast of $13.02. SunTrust Banks also issued estimates for Shire PLC’s Q4 2016 earnings at $3.30 EPS, FY2018 earnings at $18.06 EPS, FY2019 earnings at $23.08 EPS and FY2020 earnings at $26.39 EPS.
Several other equities research analysts have also commented on SHPG. Piper Jaffray Cos. set a $201.00 price objective on shares of Shire PLC and gave the stock a “hold” rating in a research note on Saturday, October 1st. Leerink Swann reissued a “buy” rating on shares of Shire PLC in a research note on Saturday, October 1st. Citigroup Inc. reissued a “buy” rating on shares of Shire PLC in a research note on Wednesday, August 3rd. RBC Capital Markets reissued an “outperform” rating on shares of Shire PLC in a research note on Wednesday, August 3rd. Finally, Zacks Investment Research raised shares of Shire PLC from a “sell” rating to a “hold” rating in a research note on Thursday, August 4th. Four equities research analysts have rated the stock with a hold rating and twenty-three have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $224.81.
Shire PLC (NASDAQ:SHPG) opened at 188.59 on Friday. The company has a 50-day moving average of $0.00 and a 200 day moving average of $0.00. Shire PLC has a 12-month low of $147.60 and a 12-month high of $219.52.
Shire PLC (NASDAQ:SHPG) last released its quarterly earnings data on Tuesday, November 1st. The biopharmaceutical company reported $3.17 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $3.21 by $0.04. The business earned $3.45 billion during the quarter, compared to the consensus estimate of $3.57 billion. Shire PLC had a return on equity of 14.81% and a net margin of 1.62%. The firm’s quarterly revenue was up 108.6% on a year-over-year basis. During the same period last year, the business posted $3.24 earnings per share.
Hedge funds have recently made changes to their positions in the stock. Quadrant Capital Group LLC boosted its stake in shares of Shire PLC by 157.6% in the second quarter. Quadrant Capital Group LLC now owns 608 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 372 shares in the last quarter. Canal Insurance CO acquired a new stake in shares of Shire PLC during the second quarter worth approximately $102,000. FTB Advisors Inc. boosted its stake in shares of Shire PLC by 3.1% in the second quarter. FTB Advisors Inc. now owns 600 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 18 shares in the last quarter. Duncker Streett & Co. Inc. acquired a new stake in shares of Shire PLC during the second quarter worth approximately $111,000. Finally, Ropes Wealth Advisors LLC acquired a new stake in shares of Shire PLC during the second quarter worth approximately $114,000. 24.22% of the stock is owned by institutional investors and hedge funds.
Shire PLC Company Profile
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.